AOD-9604 // The GH Fragment
A modified version of growth hormone's fat-burning fragment (amino acids 176-191) with an added tyrosine residue for improved stability. Stimulates lipolysis and inhibits fat formation without affecting blood sugar, IGF-1, or any GH-related side effect. One of the cleanest fat loss compounds available — TGA-approved in Australia.
Fat-specific. Nothing else.
AOD-9604 is a precision tool. By isolating the fat-metabolizing portion of growth hormone and stabilizing it with a tyrosine modification, it delivers targeted lipolysis without blood sugar disruption, water retention, or joint problems. It won't build muscle or affect sleep — it only touches fat.
Simple daily protocol.
AOD-9604's short half-life requires daily fasted administration. Inject on an empty stomach and wait 30-60 minutes before eating — insulin interferes with the fragment's activity.
TGA-approved. Mechanism proven through GH fragmentology.
AOD-9604's regulatory story is unique — the Australian TGA approved it for general sale, giving it one of the few regulatory endorsements for any fat-loss peptide. Phase 2 clinical trials demonstrated fat reduction, and the mechanism is well-characterized through decades of GH fragmentology.
The key advantage is safety through specificity. By isolating amino acids 176-191 and adding tyrosine stabilization, AOD-9604 delivers targeted lipolysis without blood sugar disruption, water retention, or joint problems. Post-marketing data from Australia provides additional safety confidence.
How it stacks against the competition.
| Compound | Receptors | Weight Loss | Half-Life | FDA Status |
|---|---|---|---|---|
| AOD-9604 | Modified GH Fragment | Moderate | ~30 min | TGA-Approved (AU) |
| Fragment 176-191 | Raw GH Fragment | Moderate | ~30 min | Research |
| Semaglutide | GLP-1 | ~15–17% | ~7 days | FDA Approved |
| 5-Amino-1MQ | NNMT Inhibitor | Mild-Moderate | Not characterized | Research |
| Tesofensine | Monoamine RI | ~12.8% | ~9 days | Phase 3 |
What to watch for.
AOD-9604's side effect profile requires careful monitoring. One of the cleanest side effect profiles in the entire fat loss category.
- Minimal reported side effects (cleanest profile in category)
- Mild injection site irritation
- Occasional headache
- No blood sugar effects, no water retention, no joint pain
- No IGF-1 elevation, no GH-related side effects
- Better tolerated than most fat loss compounds
- Fasting glucose (monitoring)
- Fasting insulin
- Lipid panel
- Standard CBC / CMP baseline
- IGF-1 (should remain unchanged)
- Stacking with Fragment 176-191 debated — overlapping mechanism
- Best paired with 5-Amino-1MQ (complementary NNMT pathway)
- Tesofensine for appetite suppression + AOD for lipolysis
- GLP-1 agonists for complementary appetite pathway
- CJC-1295/Ipamorelin if you want GH benefits beyond fat
- Can be used standalone for mild fat loss
- Refrigerate reconstituted at 2–8°C
- Use within 21 days
- Oral capsules: room temperature
- Gentle reconstitution
- Confirm tyrosine modification on COA
- ≥97% HPLC required
Compounds that complement AOD-9604.
AOD-9604 works through a single narrow pathway — so GLP-1 agonists, NNMT inhibitors, and monoamine compounds are all true complements with zero overlap.
The cleanest fat loss peptide — low risk, moderate reward.
AOD-9604 won't produce the dramatic 15-25% weight loss of GLP-1 agonists. But it also won't produce the nausea, muscle loss, or severe appetite suppression. It does one thing — break down fat — with essentially zero systemic side effects. The TGA approval adds regulatory confidence most research peptides lack. Pair with 5-Amino-1MQ for a synergistic stack hitting two independent pathways.
Our free 50-page Protocol Guide includes the complete Metabolic Fat Loss Stack with AOD-9604 — titration schedules, stacking recommendations, blood work panels, and tracking templates.